Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women

  • Andreas Lammerich, Peter Bias, Beate Gertz
  • International Journal of Women s Health, July 2015, Dove Medical Press
  • DOI: 10.2147/ijwh.s83418

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

http://dx.doi.org/10.2147/ijwh.s83418

The following have contributed to this page: Dr Andreas Lammerich and Beate Dr. Gertz